170 related articles for article (PubMed ID: 38634515)
21. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
[TBL] [Abstract][Full Text] [Related]
22. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
[TBL] [Abstract][Full Text] [Related]
23. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
Soni P; Chawla E
Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
[TBL] [Abstract][Full Text] [Related]
25. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
Suzuki K; Suzuki S; Fujita H; Sakuramoto H; Shioda M; Hirata K
Neuropsychopharmacol Rep; 2024 Jun; 44(2):482-484. PubMed ID: 38602109
[TBL] [Abstract][Full Text] [Related]
26. The role of anti-CGRP antibodies in the pathophysiology of primary headaches.
Barbanti P; Aurilia C; Fofi L; Egeo G; Ferroni P
Neurol Sci; 2017 May; 38(Suppl 1):31-35. PubMed ID: 28527063
[TBL] [Abstract][Full Text] [Related]
27. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
28. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
29. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
31. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
[TBL] [Abstract][Full Text] [Related]
32. Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention.
Regnier SA; Lee XY
J Med Econ; 2023; 26(1):1072-1080. PubMed ID: 37594778
[No Abstract] [Full Text] [Related]
33. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication-a real-world study.
Rosignoli C; Caponnetto V; Onofri A; Trozzi V; Tartaglione L; Silvestro M; Russo A; Sacco S; Ornello R
Neurol Sci; 2024 Jul; 45(7):3305-3312. PubMed ID: 38340218
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
[TBL] [Abstract][Full Text] [Related]
36. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
Israel H; Neeb L; Reuter U
Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies for the prevention of migraine.
Raffaelli B; Neeb L; Reuter U
Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
[No Abstract] [Full Text] [Related]
38. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
39. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
Kang SA; Govindarajan R
Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
Sun W; Cheng H; Xia B; Liu X; Li Y; Wang X; Liu C
Clin J Pain; 2023 Oct; 39(10):560-569. PubMed ID: 37278480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
